Daniel O’Neill

883 total citations
27 papers, 608 citations indexed

About

Daniel O’Neill is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Daniel O’Neill has authored 27 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 14 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Daniel O’Neill's work include Lung Cancer Treatments and Mutations (11 papers), Prostate Cancer Treatment and Research (8 papers) and Ubiquitin and proteasome pathways (4 papers). Daniel O’Neill is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Prostate Cancer Treatment and Research (8 papers) and Ubiquitin and proteasome pathways (4 papers). Daniel O’Neill collaborates with scholars based in United Kingdom, United States and Singapore. Daniel O’Neill's co-authors include Craig Robson, Luke Gaughan, Kelly Coffey, Steven Darby, Dominic Jones, Jacqueline Stockley, Lynsey Rogerson, Ian R. Logan, Victoria Harle and Mark Wade and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Daniel O’Neill

26 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel O’Neill United Kingdom	11	399	251	180	96	49	27	608
Jongkeun Lee South Korea	8	427 1.1×	78 0.3×	77 0.4×	200 2.1×	51 1.0×	12	541
D D Bigner United States	11	283 0.7×	115 0.5×	157 0.9×	85 0.9×	24 0.5×	14	518
Monzur Rahman United States	6	270 0.7×	39 0.2×	271 1.5×	96 1.0×	27 0.6×	7	532
A E Pegg United States	8	633 1.6×	115 0.5×	174 1.0×	180 1.9×	52 1.1×	9	840
Catherine B. Meador United States	11	352 0.9×	338 1.3×	408 2.3×	207 2.2×	26 0.5×	35	725
Jordan F. Hastings Australia	8	256 0.6×	49 0.2×	127 0.7×	106 1.1×	18 0.4×	13	455
Chang‐Uk Lim United States	13	343 0.9×	90 0.4×	176 1.0×	87 0.9×	46 0.9×	21	533
Eva María Ciruelos Gil Spain	3	253 0.6×	164 0.7×	331 1.8×	148 1.5×	80 1.6×	6	568
Longzhen Cui China	13	430 1.1×	58 0.2×	78 0.4×	260 2.7×	14 0.3×	29	614
Jenny Y. Xue United States	9	654 1.6×	133 0.5×	311 1.7×	111 1.2×	39 0.8×	16	824

Countries citing papers authored by Daniel O’Neill

Since Specialization

Citations

This map shows the geographic impact of Daniel O’Neill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel O’Neill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel O’Neill more than expected).

Fields of papers citing papers by Daniel O’Neill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel O’Neill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel O’Neill. The network helps show where Daniel O’Neill may publish in the future.

Co-authorship network of co-authors of Daniel O’Neill

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel O’Neill. A scholar is included among the top collaborators of Daniel O’Neill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel O’Neill. Daniel O’Neill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grazini, Ursula, Aleksandra Markovets, Lucy Ireland, et al.. (2024). Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations. Clinical Cancer Research. 30(18). 4143–4154. 12 indexed citations

Walker, Laura, R. Scott Duncan, Dominic Jones, et al.. (2024). Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer. Molecular Cancer Research. 22(12). 1128–1142. 2 indexed citations

Colclough, Nicola, Ravindra V. Alluri, Danxi Li, et al.. (2023). Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier. Drug Metabolism and Disposition. 52(2). 95–105. 10 indexed citations

Clausen, Maryam, Rebecca Halpin, Kang Cai, et al.. (2021). A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce. Scientific Reports. 11(1). 12676–12676. 1 indexed citations

Vaclová, Tereza, Ursula Grazini, Lewis S. C. Ward, et al.. (2021). Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications. 12(1). 1780–1780. 46 indexed citations

Pike, Andy, et al.. (2021). Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs. Drug Metabolism and Disposition. 49(9). 736–742. 3 indexed citations

Collie, Gavin W., Cheryl M. Koh, Daniel O’Neill, et al.. (2019). Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors. ACS Medicinal Chemistry Letters. 10(9). 1322–1327. 39 indexed citations

Ward, Richard A., Ambra Bianco, Nicola Colclough, et al.. (2019). Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR). Cancer Research. 79(13_Supplement). 4813–4813. 1 indexed citations

Floc’h, Nicolas, M. Raymond V. Finlay, Ambra Bianco, et al.. (2019). Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation. Cancer Research. 79(13_Supplement). 4451–4451. 9 indexed citations

10.

Floc’h, Nicolas, Matthew J. Martin, Jonathan W. Riess, et al.. (2018). Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Molecular Cancer Therapeutics. 17(5). 885–896. 85 indexed citations

11.

Shaw, Joseph, Daniel Martinez Molina, Daniel O’Neill, et al.. (2018). Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay. Scientific Reports. 8(1). 163–163. 47 indexed citations

12.

Rothberg, Bonnie Gould, Rahul Das, Laura Jackson, et al.. (2017). P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas. Journal of Thoracic Oncology. 12(1). S623–S624. 1 indexed citations

13.

Riess, Jonathan W., Nicolas Floc’h, Matthew W. Martin, et al.. (2017). Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.. Journal of Clinical Oncology. 35(15_suppl). 9030–9030. 5 indexed citations

14.

Logan, Ian R., Urszula L. McClurg, Dominic Jones, et al.. (2016). Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells. Oncotarget. 7(46). 74724–74733. 5 indexed citations

15.

O’Neill, Daniel, et al.. (2015). Evolution of the construction of Dublin City Council’s housing, with emphasis on wall construction. Structural Survey. 33(2). 109–132. 2 indexed citations

16.

O’Neill, Daniel, Stuart C. Williamson, Marilyn Goudreault, et al.. (2014). SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells. Epigenetics. 9(7). 942–950. 28 indexed citations

17.

Coffey, Kelly, Lynsey Rogerson, Jacqueline Stockley, et al.. (2013). The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Research. 41(8). 4433–4446. 99 indexed citations

18.

Gaughan, Luke, Jacqueline Stockley, Kelly Coffey, et al.. (2013). KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade. Nucleic Acids Research. 41(14). 6892–6904. 66 indexed citations

19.

Harle, Victoria, Kelly Coffey, Steven Darby, et al.. (2013). Deubiquitinating Enzyme Usp12 Is a Novel Co-activator of the Androgen Receptor. Journal of Biological Chemistry. 288(45). 32641–32650. 80 indexed citations

20.

Loddick, Sarah A., Luke Gaughan, Jim Growcott, et al.. (2012). Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer. Cancer Research. 72(8_Supplement). 3848–3848. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact